Bumper Offer - Urjas oil Just @ Rs. 1
Rafle 550 Tablet is a commercial drug that is prescribed in the form of Tablet. Hepatic Encephalopathy are some of its major therapeutic uses. Secondary and off-label uses of Rafle 550 Tablet have also been mentioned below.
The right dosage of Rafle 550 Tablet depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. Refer to the dosage section for a detailed discussion.
The side effects typically associated with Rafle 550 Tablet include Flatulence, Bloating or fullness, Constipation. Apart from the aforementioned side effects, Rafle 550 Tablet can also lead to other problems, which have been listed below. Usually, these side effects of Rafle 550 Tablet go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
Furthermore, you should know that effect of Rafle 550 Tablet is Severe for pregnant women and Severe for women who are breastfeeding. Further, the section on Rafle 550 Tablet related warnings talks about Rafle 550 Tablet's effects on the liver, heart and kidney.
Other conditions have been mentioned below in the Rafle 550 Tablet contraindications section.
Drug interactions for Rafle 550 Tablet have been reported in the medical literature. See below for a complete list.
In addition to the above precautions for Rafle 550 Tablet, it is important to know that it is safe while driving, and is habit-forming.
Rafle 550 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| 13 - 18 years (Adolescent) |
|
| Geriatric |
|
Based on research, the following side effects have been observed when Rafle 550 Tablet is used -
Moderate
Mild
Common
Is the use of Rafle 550 Tablet safe for pregnant women?
Pregnant women may get severe side effects after taking Rafle. If you are pregnant, do not take Rafle without a doctor's advice.
Is the use of Rafle 550 Tablet safe during breastfeeding?
Taking Rafle may lead to serious side effects if you are breastfeeding. Rafle should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Rafle 550 Tablet on the Kidneys?
Rafle is completely safe for kidneys.
What is the effect of Rafle 550 Tablet on the Liver?
Side effects of Rafle rarely affect the liver.
What is the effect of Rafle 550 Tablet on the Heart?
You can take Rafle without any fear of damage to the heart.
Rafle 550 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Rafle 550 Tablet unless your doctor advises you to do so -
Is this Rafle 550 Tablet habit forming or addictive?
No, there is no any evidence that Rafle 550 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Rafle 550 Tablet as it does not make you drowsy.
Is it safe?
Yes, but take Rafle 550 Tablet only as per medical advice.
Is it able to treat mental disorders?
No, the use of Rafle 550 Tablet in mental disorders is not effective.
Interaction between Food and Rafle 550 Tablet
Taking Rafle 550 Tablet with food is safe.
Interaction between Alcohol and Rafle 550 Tablet
Due to lack of research, there is no information about the side effects of taking Rafle 550 Tablet with alcohol.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xifaxan® (rifaximin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 681-683
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1096-1097
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Xifaxan® (rifaximin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 681-683
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1096-1097
